topical botulinum toxin

Topical Botulinum Toxin Moves Forward With New Funding

Topical Botulinum Toxin Moves Forward With New Funding

Anterios, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, has received $8.5 million in corporate financing, which will be used to further development of its patented topical botulinum toxin type A treatment, ANT-1207. Anterios is currently conducting Phase 2b clinical trials of ANT-1207 for clinical indications, including the treatment of lateral canthal lines, hyperhidrosis and acne. Anterios previously completed multi-center, double-blind, randomized, controlled, dose-escalation studies for each indication.